Speech services may be covered by TRICARE only when timeliness and intensity of the services needed cannot be provided by the public educational agency. For your request for authorization of speech therapy visits for your child ages 3-21 ; to be considered, Humana Military must first confirm that services cannot be received from the local school system. You will need to have the local educational agency complete an Individual Educational Program IEP ; Form. A Public Facility Use Certification Form is also acceptable and can be downloaded from the Humana Military Web site at humana-military under Forms in the Beneficiary Resources section. ; The completed IEP Form or Public Facility Use Certification Form ; should be faxed to Humana Military at 1-877-548-1547 to receive authorization.

Background. Mucosa-associated lymphoid tissue lymphoma MALT lymphoma ; of the lung is a relatively rare disease with minor growth for a prolonged period of time and the potential for late dissemination, as generally known for MALT lymphoma. Aims. As little is known about the natural clinical course of MALT lymphoma if left untreated, we have analysed all patients undergoing a watch-and-wait policy at our institution. Patients and Methods. A retrospective analysis identified a total of 11 patients with MALT lymphoma of the lung who did not undergo treatment following initial diagnosis. All patients had undergone extensive staging and were closely observed with restaging every three months. Results. Five patients 48% ; had MALT lymphoma restricted to the lung, while the remaining six patients had additional extrapulmonary sites detected during staging. The median time of observation without therapy was 26.3 months Inter-quartile range: 5 to 60 months within this time all 11 patients showed at least stable disease. Six of these 11 patients 52% ; , however, had spontaneous regressions and wax-and-wane phenomena of the pulmonary lesions, but not of extrapulmonary manifestations. Three of these patients had evidence of t 11; 18 ; q21; q21 ; , while the remaining three had no evidence of genetic aberrations. One patient was referred to treatment after progression in the lung, while two patients progressed outside the lung. Currently, all patients are alive, with 8 patients still being only watched. Discussions. Our findings suggest MALT lymphoma of the lung as a very indolent disease with the potential for spontaneous regression. In view of this, patients diagnosed with pulmonary MALT lymphoma might not need require immediate treatment in the absence of symptoms, and a watch and wait policy could be adopted.
Now, to be eligible for a diagnosis of CAFS, one must have had at least three distasteful encounters with aler ts or reminders in an electronic medical record system over a period of 24 hours, recurring at least three times per week over an interval of one month, such as the following: a duplicate drug therapy warning Example: You are an in-hospital pharmacist. A physician has just ordered milk of magnesia MOM ; suspension for a constipated patient who is already receiving oral docusate sodium Colace, Purdue Pharma ; capsules; the database system sends you a warning indicating that MOM and Colace are from the same class, "laxatives, " a one-two punch that the physician intended to order. a reminder to counsel a patient about smoking cessation Example: You are a nurse. You have already documented that you counseled the patient about quitting smoking, but the system can't see your note, which is still on paper. As a result, the system keeps prompting you to address smoking cessation with your patient. an alert to be cautious about using vancomycin therapy Example: You are an infectious-disease specialist. You need to order vancomycin frequently for your seriously ill patients with infections caused by beta-lactam resistant, gram-positive organisms. Each time you place an order for vancomycin, an educational warning is displayed about the fact that vancomycin use is a risk factor for infection and colonization with vancomycinresistant enterococcus VRE ; . You are asked to document your reason for ordering this product. To be given the diagnosis of CAFS, one also must have experienced a certain constellation of symptoms, satisfying three major criteria or two major plus two or more ; minor criteria, as follows: major criteria fatigue.

Human development and recreation activities influence the extent and condition of riparian zones. Developed camping areas are located adjacent to Mitchell Creek, Big Creek, Prince Creek, Fish Creek and the Stehekin River. There is an undeveloped campsite located at Grade Creek. These camping areas, particularly Mitchell Creek, Prince Creek, Fish Creek and the Stehekin River, were heavily used during field studies conducted in 1999. Although most recreation activity was concentrated within the designated camping areas and trails, some activity was noted within riparian habitats. This may result in the trampling or cutting of riparian vegetation and disturbance of wildlife. Campers and day-users were also observed at Grade Creek; uncontrolled use of this area was partly responsible for somewhat degraded riparian conditions near the mouth of the creek. However, recreation activities are a relatively insignificant factor influencing riparian habitats compared to human development. There is considerable residential development near the mouth of the Stehekin River where native vegetation has been removed and low areas filled-in. This development consists primarily of seasonal homes. Much of the development at the Stehekin River is adjacent to high quality riparian habitats, and human disturbance to riparian habitats and wildlife probably occurs. Although no dwellings were located near the other tributaries studied, there is development occurring within the alluvial fans of other tributaries to Lake Chelan FERC 2002. 4 Physiological measures An automated blood pressure monitor was used to measure systolic and diastolic pressure, and heart rate NBS Medical Services, Costa Mesa, Calif., USA ; . A pulse oximeter was used to monitor arterial blood oxygen saturation Palco Labs ; . Thermocouples were used to measure skin temperature Cole-Parmer ; . A specially modified Polaroid camera with a close-up lens 2 magnification ; was used to take pupil photographs. All photographs were taken under constant ambient lighting conditions. Horizontal and vertical measurements of pupil diameter were made using a caliper, and these two measurements were averaged and divided by 2 to correct for the 2 magnification. Drugs Participants were stabilized and maintained on oral morphine sulfate 30 mg qid; liquid suspension; Roxane Laboratories, Inc., Columbus, Ohio, USA ; during the hospital stay. Morphine was administered daily at 0700, 1300, 1900, and 2300 hours. Supplemental medications available to all participants for the duration of the study included: acetaminophen, ibuprofen, calcium carbonate, magnesium hydroxide, docusate sodium, and multi-vitamins with iron. Clonidine HCl 0.3 mg PO, every 8 h; Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Conn., USA ; , ketorolac tromethamine 30 mg PO, every 12 h; Roche Laboratories, Nutley, N.J., USA ; , and oxazepam 30 mg PO, every 12 h; Wyeth-Ayerst Laboratories, Philadelphia, Pa., USA ; were available, as needed, for the first 3 days after admission into the hospital while participants were stabilized on the morphine maintenance dose. Stability was defined as no subjective or objective withdrawal effects. Morning urine samples were collected daily and one random sample per week was screened for the presence of other illicit substances. No illicit substances were found in the participants' urines. Naloxone HCl Narcan; DuPont Pharma, Wilmington, Del., USA ; was administered in IM doses of 0.4 mg. Memantine Akatinol Memantine; Merz Pharma, Frankfurt Main, Germany ; was administered in a single dose of 60 mg, the maximal dose recommended for the treatment of spasticity. Statistical analyses Data analyses were conducted using SYSTAT, SuperANOVA and Statistica software. In the analysis of naloxone-precipitated opioid withdrawal, four specific questions were addressed: 1 ; Does a naloxone challenge produce significant changes in measures of opioid withdrawal? 2 ; Does memantine decrease the signs and symptoms of opioid withdrawal? 3 ; If so, how long does this diminution last? 4 ; What is the duration and severity of withdrawal in relation to the administration of memantine? Repeated measures analyses of variance ANOVA ; examined the effect of memantine on naloxone-precipitated withdrawal as measured by CINA, OOWS and SOWS scores, subjective effects, performance, and physiological measures ; with time relative to memantine administration 42 h, + 6 h, 126 h ; and time relative to naloxone administration 10 min, + 10 min, + 20 min, + 30 min, + 45 min, + 60 min ; as within-subjects measures. All measures returned to baseline values 60 min after the injection and therefore values obtained at + 90 min were omitted from the final analyses. Data for each challenge 10 to + min ; were also summarized as the area under the curve AUC ; calculated using the trapezoidal method and analyzed independently using ANOVA. Significant interaction effects were examined using NewmanKeuls multiple comparisons procedure. General linear regression models were used to examine the influence of number of baseline naloxone challenge days and severity of initial withdrawal on memantine response. The effects of memantine alone on DEQ, task performance, and subjective effects scores were examined by comparing the effects of memantine with the effects of placebo that was given on the last of the baseline days, 42 h before administration of memantine. Results were considered statistically significant at P 0.05.
Choices and Weight Outcomes. The analysis is based on data from USDA's 1994-1996 Continuing Survey of Food Intakes by Individuals and the 1994-1996 Diet and Health Knowledge Survey. The analysis found: Men and women who live in the West have a higher quality diet and drink fewer sugary beverages. Men and women in rural areas have a lower quality diet. Men who live in urban areas are more likely to believe that their body weights are healthy when in fact they are overweight or obese. Women in the South eat breakfast more often than women in other regions. Compared with all other explanatory variables, income had the strongest marginal impact on diet quality and the amount of time spent watching TV. Both men and women with higher incomes watch less TV and eat a higher quality diet. Women with higher incomes drink fewer sugary beverages, such as fruit drinks and soft drinks, and have a higher sense of self-efficacy regarding weight control. Also, a higher proportion of women with higher incomes indicate that they exercise at least once a week. Men with higher incomes are more accurate in reporting their weight status. Compared with all other explanatory variables, household structure has the largest impact on an individual's consumption of sugary beverages and whether he or she consumes breakfast. Men and women who are married with children drink fewer sugary beverages, and eat breakfast more often than single parents. They also have a higher quality diet and zometa.

What is docusate sod 10 will be followed with CBCs, Hb F levels, and Erythropoietin levels every 2 weeks for 2 months, or until the CBCs return to baseline. This will allow a determination of how long the effects of the drug persist. 5. BUTYRATE + ERYTHROPOIETIN study weeks 27-40 ; Patients will be offered participation in the study of the combination of Butyrate + EPO, unless he she has a medical contraindication such as paraspinal extramedullary hematopoiesis, hypertension, or poorly controlled congestive heart failure. Results of the combined treatment will be compared to results achieved on butyrate alone in each patient ; . Butyrate will be continued on alternate weeks. EPO will be given three times per week, IM or sub Q. Initial dose will be 300 U kg, and 500 U kg during week 34 if there is no response. Laboratory studies will be performed as shown below. Optimal Butyrate Dose, 4 nights week EPO 300-500 u kg * 3x week X Lab Studies. LANACANE is an anaesthetic cooling cream. The active ingredient is Benzocaine 3% w w. It formulated to provide fast relief from itching and irritation. Benzocaine works on the skin surface to anaesthetise skin cells, to stop itching and irritation fast and eliminate the urge to scratch. LANACANE also contains Chlorothymol, Diethylene Glycol Monoethyl Ether, Docuszte Sodium, Perfume, Glycerol, Glycerol Monostearate, Isopropyl Alcohol, Stearic Acid, Sulfonated Castor Oil, Trolamine, Purified Water, Zinc Oxide. LANACANE is available in tubes of 30g and 60g. The Marketing Authorisation for Lanacane is held by Combe International Ltd., Croydon, Surrey, CR9 2AU, U.K. The manufacturer is Laleham Healthcare, Alton, Hants, GU34 2QR, U.K and lamictal. Since to date no paediatric trial has sufficiently established correct dosing of iv preparations in children, use of iv busulphan is prohibited within this phase III study setting due to the risks of over and underdosing in children. Only after sufficient data is established, an amendment to this phase III protocol may be envisaged.

Docusate sodium mg Pituitary Surgery Many of our patients have transphenoidal resection of pituitary tumors. They often have pituitary hormone deficiencies i.e. cushings disease, prolactinoma, acromegaly ; . All these patients have endocrinology and ENT following them. ENT manages the nasal packing. If there was a CSF leak in surgery then the patients will have a lumbar drain for 3 days. Dripping of clear fluid from the nose should be noted and reported to the resident. Endocrinology will typically order postoperative cortisol levels. Let them manage the hormone replacement and nitrofurantoin. Antidiarrheal: Bismuth Subsalicitate Pepto-Bismol ; 262mg Loperamide Imodium ; 2mg cap Anti-inflammatory bowel ; Mesalamine Asacol ; 400mg tab, Mesalamine SR Pentasa ; 250mg cap Sulfasalazine En-tab ; 500mg EC tab Antispasmotics Hyos Atrop Scop Phenobarb Donnatal ; tab Donnatal elixer Dicyclomine Bentyl ; 20mg tab Cathartic Laxative Bisacadyl Dulcolax ; 5mg tab Biscadyl 10mg rectal supp Docusaate sodium Colace ; 100mg cap Doc7sate sodium 20mg 5ml syrp Electrolyte Peg Sol Golytely ; 4000ml Enema , pediatric Fleet ; 67ml Enema, adult 133ml Fleet Phospho-soda 45ml solution Glycerin Supp Pediatric and Adult Citrate of Magnesium 300ml Lactulose 10gm 15ml syrup Mineral Oil Miralax Powder 527gm bottle Psyllium 397gm bottle Senna Senokot ; 8.6mg tab Sod Chlor NAC03 KCL PEG's Nulytely ; Ulcer Esophagitis Cimetidine Tagamet ; 400mg tab Ranitidine Zantac ; 150mg Ranitidine 15mg ml syrup Esomeprazole Nexium ; 20, 40mg cap Omeprazole Prilosec ; 20mg cap GI Misc Belladonna Phenobarbital ergotamine Bellergal S ; 0.2mg 40mg 0.6mg tab Metoclopramide Reglan ; 10mg tab Metoclopramide 5mg 5ml soln Misoprostol 100mcg tab Pancrealipase Lipram ; CR 20, 4500mg cap Simethicone Mylicon ; 80mg chew Simethicone 40mg 0.6ml drops Sucralfate Carafate ; 1gram tab. Chemistry & Environment Consultants has been a wholly owned subsidiary of Apoteket since 1993. It is a consultant company which supports leading executives to create sustainable development for their business. By sustainable development is meant the integration of environmental concern, quality, the work environment, and social issues in the day-to-day duties of the business. Besides this, Chemistry & Environment Consultants carries out assessment of the health and environmental risks of products. The average number of those employed there is 21. QUALITY Increased demands on Apoteket's operations entail being able to quickly adapt goods and services to the needs of customers and society. In the process of doing this it is important to monitor and improve quality and safety and imodium.

Stimulant laxatives: Senna Docusa6e Sodium Locally administered laxatives: Glycerol Sodium Citrate Arachis Oil 1.7 Preparations for haemorrhoids Soothing preparations: Anusol Compound preparations: Anusol HC Xyloproct. Environmental , chemistry & hazardous materials news, careers & resources skip to page content skip to ad free user log in skip to site menu on this page chemical database succinic acid, sulfo-, 1, 4-bis 2-ethylhexyl ; ester, sodium salt identifications cas number: 577-11-7 synonyms related: 1, 4-bis 2-ethylhexyl ; sodium sulfosuccinate 1, 4-bis 2-ethylhexyl ; sulfobutanedioate, sodium salt 2-ethylhexyl sulfosuccinate sodium adekacol ec 8600 aerosol a 501 aerosol aot aerosol gpg aerosol ot aerosol ot 70pg aerosol ot 75 aerosol ot-a alcopol o alkasurf ss-o 75 alphasol ot berol 478 bis 2-ethylhexyl ; s-sodium sulfosuccinate bis 2-ethylhexyl ; sodium sulfosuccinate bis 2-ethylhexyl ; sulfosuccinate sodium salt bis 2-ethylhexyl ; sulfosuccinate, sodium salt bis 2-ethylhexyl ; sodium sulfosuccinate bis ethylhexyl ; ester of sodium sulfosuccinic acid bis-2-ethylhexylester sulfojantaranu sodneho butanedioic acid, sulfo-, 1, 4-bis 2-ethylhexyl ; ester, sodium salt c06968 celanol dos 65 celanol dos 75 clestol colace colace tn ; complemix constonate coprol correctol caplets correctol extra gentle tablets correctol tablets d-s-s d-s-s plus d00305 defilin dess di 2-ethylhexyl ; sulfosuccinic acid, sodium salt di- 2-ethylhexyl ; sodium sulfosuccinate dialose plus dioctlyn dioctyl ester of sodium sulfosuccinate dioctyl ester of sodium sulfosuccinic acid dioctyl sodium sulfosuccinate jan ; dioctylal diomedicone diosuccin diovac diox disonate docusate sodique docusate sodium docusate sodium usp ; docusate sodium docusato sodico docusatum natricum dorbantyl doxinate doxol dulsivac duosol feen-a-mint pills geriplex humifen wt 27g konlax kosate laxinate laxinate 100 manoxal ot manoxol ot mervamine modane soft molatoc molcer molofac monawet md 70e natrii dioctylsulfosuccinas nekal wt-27 nevax nikkol otp 70 norval obston peri-colace regutol requtol revac sanmorin ot 70 sbo senokap dss senokot s sobital sodium 1, 4-bis 2-ethylhexyl ; sulfosuccinate sodium 2-ethylhexylsulfosuccinate sodium bis 2-ethylhexyl ; sulfosuccinate sodium bis 2-ethylhexyl ; sulfosuccinate sodium di 2-ethylhexyl ; sulfosuccinate sodium di- 2-ethylhexyl ; sulfosuccinate sodium dioctyl sulphosuccinate sodium sulfodi- 2-ethylhexyl ; -sulfosuccinate softil sol sodowej sulfobursztynianu dwu-2-etyloheksylowego soliwax solusol-100% solusol-75% succinic acid, sulfo-, 1, 4-bis 2-ethylhexyl ; ester, sodium salt sulfimel dos sulfosuccinic acid, bis 2-ethylhexyl ; ester sodium salt sulfosuccinic acid, di- 2-ethylhexyl ; ester, sodium salt sv 102 tex-wet 1001 triton gr 7 triton gr-5 unilax velmol waxsol wetaid sr related resources usdot hazardous materials table 49 cfr 17 101 an online version of the usdot's listing of hazardous materials from 49cfr 17 10 this table can be sorted by proper shipping name, un na id and or by primary hazard class division and meclizine. Constipation CONSTIPATION DUE TO MEDICATION? e.g. narcotics or chemotherapy 1. DIETARY MEASURES Increase consumption of fluids & fibre-containing foods such as bran, fruits & vegetables, prune juice and figs. Drink 8 or more glasses of non-caffeinated liquids each day. 2. NORMAL BOWEL HABITS, e.g. do not delay bowel movements. Try stimulant laxative, SENOKOT senna ; : 1 to tablets twice daily in the morning and in the evening ; , starts working in 6 to hours maximum dose 8 tablets day ; AND OR Stool softeners: COLACE docusate sodium ; 100mg capsules: 1 to 2 twice daily, each morning and evening, starts working in 12 to hours. SURFAK Docuate Calcium ; 240mg capsules: 1 to 2 capsules daily may be taken once or twice daily ; , starts working in 12 to hours.
Preferred drugs that used to require diag codes still require diag codes unless indicated otherwise. * BISAC-EVAC SUPP ACTIGALL CAPS MC DEL BISACODYL BISCOLAX SUPP CINOBAC CAPS CITRATE OF MAGNESIA SOLN CITRUCEL D.O.S. CAPS DIOCTO LIQD DIOCTO SYRP DIOCTYN CAPS DOC-Q-LACE CAPS DOCUSATE CALCIUM CAPS DOCUSATE SODIUM DOCUSIL CAPS DOK CAPS FIBER LAXATIVE TABS FLEET GENFIBER POWD GLYCERIN HIPREX TABS KRISTALOSE PACK METAMUCIL MILK OF MAGNESIA SUSP MINERAL OIL OIL MIRALAX POWD 1 SENNA SENOKOT GRAN SENOKOT SYRP SENOKOT CHILDRENS SYRP SENOKOT XTRA TABS SORBITOL STOOL SOFTENER CAPS SUCRALFATE TABS UNI-EASE CAPS UNIFIBER POWD URSODIOL MISC. UROLOGICAL ACETIC ACID 0.25% SOLN BICITRA SOLN CYTRA-K SOLN FURADANTIN SUSP K-PHOS MF TABS MACRODANTIN CAPS METHENAMINE MANDELATE TABS MONUROL PACK NEOSPORIN GU IRRIGANT SOLN PHENAZOPYRIDINE HCL TABS PHOSLO and antivert.
Patients should be told to be cautious about driving or operating heavy machinery until they know how acamprosate will affect their ability to engage in these activities and until they have adjusted to any effects of the drug. In clinical trials, suicidal events suicidal ideation, attempted suicides, completed suicides ; , although rare, were more common in acamprosate-treated participants than in participants receiving placebo. Patients should be monitored for symptoms of depression or suicidal thinking. Families and caregivers should be informed of the need to monitor their family members for these signs and report their occurrence to the substance abuse treatment counselor or prescribing professional. Use of acamprosate during pregnancy has not been studied with humans. Animal studies of acamprosate and pregnancy have found some potential fetal risk. The potential risk of taking acamprosate during pregnancy should be balanced with the potential benefits considering the known adverse effects of alcohol, particularly the risk of fetal alcohol syndrome ; . The use of acamprosate by older adults or by children has not been studied. Because of the higher risk of diminished renal function among older adults, acamprosate should be used with caution with this population. 1. Quaker Medical Associates 7. Gabryel, Kelly & Mazepa, Jamestown 2. Niagara Falls Memorial Primary Care Medical Center, MSO 8. Associated Physicians of WNY, 3. Hartrich, Aquino & Hrab Northtowns Medical Group, 4. Frankfort, Rubin & McMahon Westfield Family Physicians 5. Lifetime Health, Amherst 9. Buffalo Medical Group, Family Care 6. Kenmore Family Medicine, LLP, Physicians, General Physician, PC, Lifetime Health-Sheridan Drive Jamestown Area Medical Association Lifetime Health-West Seneca 10. Highgate Medical Group, Lifetime Health-Hamburg, Medical Associates Southtowns, Promedicus Health Group and colace.

Population movement. For these reasons, cohort studies are more appropriate for stable, long-term refugee camps.

Measure #72: Chemotherapy for Stage III Colon Cancer Patients DESCRIPTION: Percentage of patients aged 18 years and older with Stage IIIA through IIIC colon cancer who are prescribed or who have received adjuvant chemotherapy during the 12-month reporting period INSTRUCTIONS: This measure is to be reported a minimum of once per reporting period for all patients with colon cancer seen during the reporting period. It is anticipated that clinicians who treat patients with Stage IIIA through IIIC colon cancer will submit this measure. This measure is reported using CPT Category II codes: ICD-9 diagnosis codes, CPT E M service codes, and patient demographics age, gender, etc. ; are used to identify patients who are included in the measure's denominator. CPT Category II codes are used to report the numerator of the measure. When reporting the measure, submit the listed ICD-9 diagnosis codes, CPT E M service codes, and the appropriate CPT Category II codes OR the CPT Category II code s ; with the modifier. The modifiers allowed for this measure are: 1P- medical reasons, 2P- patient reasons, 3P- system reasons, 8P- reasons not otherwise specified. NUMERATOR: Patients who are prescribed or who have previously received adjuvant chemotherapy * during the 12 month reporting period Definition: * According to current NCCN guidelines, the following therapies are recommended: 5-fluorouracil leucovorin or capecitabine, or 5-fluorouracil leucovorin oxaliplatin NUMERATOR NOTE: The correct combination of numerator code s ; must be reported on the claim form in order to properly report this measure. The "correct combination" of codes may require the submission of multiple numerator codes. Numerator Coding: Adjuvant Chemotherapy Prescribed or Previously Received Two CPT II codes [4180F & 33xxF] are required on the claim form to submit this category ; CPT II 4180F: Adjuvant chemotherapy prescribed or previously received for Stage IIIA through Stage IIIC colon cancer AND CPT II 3309F: AJCC Cancer Stage IIIA, documented OR CPT II 3310F: AJCC Cancer Stage IIIB, documented OR CPT II 3311F: AJCC Cancer Stage IIIC, documented and depakote.

The U.S. Food and Drug Administration has announced the approval of oxaliplatin EloxatinTM, Sanofi-Synthelabo, New York, NY ; , in combination with fluorouracil and leucovorin for patients with advanced colorectal cancer that has recurred or progressed following bolus therapy with fluorouracil, leucovorin, and irinotecan. The approval is based on response rates and improved time-to-tumor progression. An ongoing clinical trial is assessing whether results include a survival benefit or improvement in disease-related symptoms. The initial review of the clinical trial demonstrated a significantly better response rate of Eloxatin with fluorouracil and leucovorin, compared to fluorouracil and leucovorin alone or to Eloxatin alone. The median time-to-tumor progression increased by approximately two months in the Eloxatin fluorouracil leucovorin arm to 4.6 months, compared to 2.7 months for the fluorouracil leucovorin arm and 1.6 months for the Eloxatin alone arm. Common adverse side effects for Eloxatin include peripheral neuropathy, nausea, vomiting, diarrhea, abdominal pain, stomatitis, dyspnea, and fatigue. Eloxatin can increase the diarrhea and immunosuppression normally associated with fluorouracil or leucovorin. Eloxatin is associated with pulmonary toxicity that can be fatal and acute and persistent peripheral neuropathy. Anaphylactic-like reactions to Eloxatin have been reported and may occur within minutes of Eloxatin administration. An acute syndrome of pharyngolaryngeal dysesthesia characterized by dysphagia or dyspnea also may occur. The initial report of the early findings from the clinical trial can be found in the Journal of Clinical Oncology Vol. 18, pp. 29382947 ; . More information and full prescribing information can be found by calling 800-446-6267 or visiting SanofiSynthelaboUS.

The Merck Stock Investment Plan the "Plan" ; of Merck & Co., Inc., a New Jersey corporation "Merck" or the "Company" ; , provides participants with a convenient and economical method of purchasing shares of Merck's common stock, $.01 par value per share "Common Stock" ; , and reinvesting cash dividends paid on Common Stock in additional shares of Common Stock. Participation in the Plan is open to any registered holder of Common Stock or to any person who becomes a registered holder of Common Stock by enrolling in the Plan, paying a one-time enrollment fee of and either making an initial investment of at least 0 or authorizing automatic monthly cash investments of at least . Beneficial owners of Common Stock whose only shares are registered in names other than their own e.g., held in street name in a brokerage account ; are not eligible until they become stockholders of record either by withdrawing the shares from their brokerage account and registering the shares in their own name or by enrolling in the Plan in the same manner as a non-stockholder. Participants in the Plan may elect to have the cash dividends paid on all or a percentage of their shares of Common Stock automatically reinvested in additional shares of Common Stock. Participants may also purchase additional shares of Common Stock by making optional cash investments in accordance with the provisions of the Plan. Holders of Common Stock who choose not to participate in the Plan will continue to receive cash dividends on shares of Common Stock registered in their name, as declared, by check or direct deposit. Shares of Common Stock purchased by participants in the Plan may be treasury or new issue Common Stock or, at Merck's option, Common Stock purchased in the open market or in negotiated transactions. Treasury or new issue Common Stock are purchased from Merck at the market price on the applicable investment date. The price of Common Stock purchased in the open market or in negotiated transactions is the weighted average price at which the shares are actually purchased. The Plan supersedes the Merck & Co., Inc. Automatic Dividend Reinvestment and Cash Payment Plan in its entirety. A complete description of the Plan begins on page 4 of this Prospectus. Shares of Common Stock offered under the Plan to persons who are not currently stockholders of Merck are offered through Wells Fargo Investments, LLC, a registered broker dealer. Please read this Prospectus carefully before investing and retain it for your future reference.
If you are still having hard stools using docusate sodium at night, start drinking a teaspoon full of metamucil powdered fiber ; every morning in a glass of water.